IOPtima

IOPtima, established in 2002, is a medical device company focused on developing and commercializing treatments for ophthalmic conditions. In a significant milestone, the company was acquired by Chengdu Kanghong Pharmaceutical Group, a China-based pharmaceutical company, in a multi-stage deal that began in November 2017. At the time of the acquisition, IOPtima was led by CEO Ronen Castro, a seasoned professional in the medical device industry. The acquisition aimed to deepen the company's market penetration, particularly in China. Currently, the company is led by CEO Eran Kaplan.

The company's business model centers on the sale of its surgical systems and related products to ophthalmic clinics and hospitals. Revenue is generated through the sale of these capital equipment pieces and likely through associated consumables and service contracts. They operate in the global ophthalmic device market, with regulatory approvals in Europe, China, Canada, and Mexico, among other territories. This business is supported by a global distribution network to ensure high standards of service and product availability to its international client base.

IOPtima's flagship product is the IOPtimate® system, a surgical device for the treatment of glaucoma. This system utilizes CO2 laser technology to perform a non-penetrating deep sclerectomy, a procedure called CLASS (CO2 Laser Assisted Sclerectomy Surgery). The key benefit of this approach is its ability to reduce intraocular pressure by restoring the eye's natural fluid drainage without entering the eyeball, which lowers the risk of complications compared to traditional procedures like trabeculectomy. The CO2 laser's properties allow for precise and controlled removal of scleral tissue, and since the laser's energy is absorbed by the aqueous humor, it prevents accidental penetration into the eye. The system offers surgeons control over treatment parameters and can be used as a standalone procedure or in combination with cataract surgery. Beyond glaucoma, IOPtima also offers products for other ophthalmic applications, including the iLid™ for oculoplastic surgery and skin resurfacing, and Lipitear™ Multi, a microemulsion for treating ocular surface disorders.

Keywords: ophthalmic devices, glaucoma surgery, CO2 laser, medical laser system, IOPtimate, non-penetrating sclerectomy, CLASS procedure, intraocular pressure, oculoplastics, ocular surface disorder, Chengdu Kanghong Pharmaceutical, medical technology, surgical instruments, eye surgery, ophthalmology, minimally invasive surgery, deep sclerectomy, laser-assisted surgery, ophthalmic treatment